FDA Approves Trazimera (trastuzumab-qyyp), a Biosimilar to Herceptin

March 11, 2019 - Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Trazimera (trastuzumab-qyyp), a biosimilar to Herceptin® (trastuzumab),1 for the treatment of human epidermal growth factor...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news